HOME >> MEDICINE >> NEWS
NIAID Ebola vaccine enters human trial

quency.

On November 17, 2003, the World Health Organization reported 11 cases of Ebola hemorrhagic fever in the Republic of the Congo. Dr. Nabel notes, "The current Ebola outbreak in the Congo provides a stark reminder of the need to rapidly develop vaccines against such perilous infections. A few years ago, we did not imagine that our vaccine would enter human trials so quickly, but the re-emergence of such viruses makes it all the more important to respond quickly. Individuals who volunteer for these vaccine trials can help us understand if our new vaccines ultimately will be effective."

Twenty-seven volunteers between the ages of 18 and 44 will participate in the study. Six people will receive a placebo injection and 21 will receive the investigational vaccine, manufactured by Vical Inc., a San Diego biotechnology company working in collaboration with the VRC. Vical has also secured a nonexclusive license from NIH to proprietary gene sequences used in the DNA Ebola vaccine. In the new trial, volunteers will receive three injections over two months and will be followed for one year. Volunteers will not be exposed to Ebola virus. Individuals interested in enrolling in the trial may visit http://www.clinicaltrials.gov or call the VRC toll-free at 1-866-833-LIFE (5433).

The candidate vaccine is synthesized using modified, inactivated genes from Ebola virus. This gives the immune system information about viral structures so that it can mount a rapid defense should the real virus ever be encountered. There is no infectious material in the vaccine, and the virus was not present during any stage of the manufacturing process, notes Barney Graham, M.D., Ph.D., director of the clinical trials unit of the VRC. "It is impossible for the vaccine to cause infection," he adds, "because it employs new technology known to safely stimulate broad immune responses."

Besides assessing the vaccine's safety, re
'"/>

Contact: Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
18-Nov-2003


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAID Ebola vaccine enters human trial

(Date:7/31/2014)... 31, 2014 Loffler Companies, the leading ... was recognized by Microsoft as a Microsoft Community Connections ... Conference on July 14, 2014. , The Microsoft ... Providers that deliver cloud-based IT services and solutions to ... as an U.S. SMB Champions Club member, Loffler has ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Perhaps some people ... we are getting old from the first day when we ... of ups and downs during their whole life. Some people ... countries (like China), it is not necessary for people to ... to help; FODAY Auto, a famous China automobile manufacturer ...
(Date:7/31/2014)... “Bivalent, Heteronomy and Natural Killer Cells?” opened ... bands ~ homeostatic CS science is the answer.” , ... new on the Bryan William Brickner Blog, ten ... cannabinoid system (CS). The line-up links to PubMed articles ... directly on homeostasis, two each on the central nervous, ...
(Date:7/31/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on nine secrets that addicts don’t ... that they can spot an addict from a mile away, ... best Drug Rehabilitation’s CEO Per Wickstrom . “However, take ...
(Date:7/31/2014)... 2014 Continuing Education Company Inc ... Clinical Issues in Primary Care Continuing Medical ... at the Wailea Beach Marriott Resort and Spa on ... been developed for today's Primary Care practitioners. In 5 ... says Barbara Lyons, VP Education. , The agenda for ...
Breaking Medicine News(10 mins):Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 3Health News:FodayAuto.com: Do Not Be Afraid of Getting Old 2Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3
(Date:7/31/2014)... New York , July 31, 2014 ... Global and China Insulin Market (Rapid-Acting, Short-Acting, ... Industry Analysis, Size, Share, Growth, Trends and Forecast (Value ... Forecasts Research Report. Diabetes, growing at an ... The disease has emerged as a major cause of ...
(Date:7/30/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today ... June 28, 2014. Third Quarter Financial Highlights ... $632.6 million, reflecting operational growth of 0.5% and a ... period in the prior year. , Revenues grew ... Health revenues grew 3.5%. , GYN Surgical revenues ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
Breaking Medicine Technology:The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 3The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 4The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 5The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 6The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 7The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5
Cached News: